Objective To investigate the clinical effict of 0.01% atropine for myopia progression in school children, and to provide a reference for probing into an effective methods of preventing myopia among children.
Methods Thirty children, with a median age of 10 years (range 7-17), were given topical treatment with preservative-free 0.01% atropine eye drops in both eyes before going to bed every night, and the efficacy and safety were analyzed 12 months later. Efficacy was assessed every 6 months. In 10 children, treatment of the second eye was delayed by one day to allow for a controlled safety assessment of side effects such as dilated pupils, hypoplasia and decreased myopia.
Results In terms of myopia treatment, after 12 months of treatment with 0.01% atropine, it was 0.43 D/year( t = 8.66, P<0.01). In terms of safety, in the 10 children’s treatment of the second eye was delayed by one day, the measurable side effect was the induction of 1 mm pupil dilatation, and there was no other significant abnormalities were observed.
Conclusion Topical low-dose (0.01%) atropine is safe and effective in school-age children, and it has certain clinical promotion value.
【摘要】 目的 观察0.01%阿托品滴眼液对进展性近视学龄儿童的治疗情况, 为探寻有效的儿童近视防治措施提供参考。 方法 随机数字表法选取合肥市城区30例进展性近视学龄儿童, 年龄中位数为10(7~ 17)岁, 在每晚睡前双眼使用不含防 腐剂的0.01%阿托品滴眼液进行局部治疗, 12个月后对疗效和安全性进行分析, 每6个月对疗效进行1次评估。其中10 例患者第二只眼睛的治疗延迟1 d, 以便对瞳孔扩大、调节反应、视敏度进行可控的安全性评估。 结果 在近视治疗效果方 面, 0.01%阿托品治疗12个月后, 为0.43 D/年 (t = 8.66, P<0.01)。在安全性方面, 在10例第二只眼睛治疗延迟1 d的患者 中, 可观察到的副作用是诱导了 1 mm的瞳孔扩大;而在调节力、视近敏度及眼压等观察中, 未见明显异常。 结论 0.01% 阿托品滴眼液在治疗学龄儿童近视中安全有效, 具有一定临床推广价值。